Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL

Article
Conference|PER® Congress on Hematologic Malignancies (Winter Hematology®)

A multitude of PI3K and BTK inhibitors are currently in development that offer distinct advantages over existing treatments for patients with relapsed chronic lymphocytic leukemia.

Susan M. O’Brien, MD

With the onslaught of new PI3K and BTK inhibitors currently in development for patients with relapsed chronic lymphocytic leukemia (CLL), it is challenging to know which therapies are truly “next-generationâ€

Related Videos
Bhagirathbhai Dholaria, MBBS, associate professor, medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD
Jennifer Brown, MD, PhD
Samer A. Srour, MB ChB, MS
Rebecca L. Porter, MD, PhD
Deborah J. Wong, MD, PhD
Michael R. Migden, MD
Saad J. Kenderian, MB, CHB
Eduardo Sotomayor, MD
Related Content
FDA

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Houston Wyatt, Vanderbilt Specialty Pharmacy, Vanderbilt Health

CLL/SLL Therapy Initiation at Specialty Pharmacies May Increase Treatment Adherence Rates

April 18th 2024
Article
Talal Hilal, MD, MB, BCh

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023
Podcast
Richard Maziarz, MD, medical director, Blood & Marrow Transplant & Cellular Therapy Program, Oregon Health and Science University

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

April 16th 2024
Article
Thomas Powles, MD, MBBS, MRCP

Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC

April 16th 2024
Article